svir with inducers of P-glycoprotein (P-gp) and CYP3A4, such as St. John's wort, Hypericum perforatum. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a P-gp and CYP3A4 substrate.
Streptogramins: Use caution when administering velpatasvir with dalfopristin; quinupristin. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Quinupristin is a potent CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Sulfamethoxazole; Trimethoprim, SMX-TMP, Cotrimoxazole: Use caution when administering velpatasvir with trimethoprim. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Velpatasvir is a CYP2C8 substrate; trimethoprim is an inhibitor of CYP2C8.
Suvorexant: Use caution when administering velpatasvir with suvorexant. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); suvorexant is an inhibitor of P-gp.
Tacrolimus: Use caution when administering velpatasvir with tacrolimus. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP); tacrolimus is an inhibitor of both P-gp and BCRP.
Tamoxifen: Use caution when administering velpatasvir with tamoxifen. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); tamoxifen is an inhibitor of P-gp. Tamoxifen is also an inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Tedizolid: If possible, stop use of sofosbuvir temporarily during treatment with oral tedizolid. If coadministration cannot be avoided, closely monitor for sofosbuvir-associated adverse events. Sofosbuvir plasma concentrations may be increased when administered concurrently with oral tedizolid. Sofosbuvir is a substrate of the Breast Cancer Resistance Protein (BCRP); oral tedizolid inhibits BCRP in the intestine. If possible, stop use of velpatasvir temporarily during treatment with oral tedizolid. If coadministration cannot be avoided, closely monitor for velpatasvir-associated adverse events. Velpatasvir plasma concentrations may be increased when velpatasvir is administered concurrently with oral tedizolid. Velpatasvir is a substrate of the Breast Cancer Resistance Protein (BCRP); oral tedizolid inhibits BCRP in the intestine.
Telithromycin: Use caution when administering velpatasvir with telithromycin. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); telithromycin is a weak inhibitor of P-gp. Telithromycin is also a potent inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Temsirolimus: Use caution if coadministration of temsirolimus with velpatasvir is necessary, and monitor for an increase in temsirolimus- and velpatasvir-related adverse reactions. Temsirolimus is |
